Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib

"A 53-year-old female ex-smoker (10 pack-years) presented with progressive dyspnea in February 2014. Her performance status was 1. She was diagnosed with stage IV lung adenocarcinoma with lung, lymph node, and bone involvement. Molecular testing revealed an ALK receptor tyrosine kinase (ALK) translocation with no other concomitant alterations. Our case describes a patient with ALK-rearranged NSCLC who developed pulmonary toxicity on brigatinib that recurred after exposure to lorlatinib at early onset. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.06.013

Authors: Xavier Monzonís, Edurne Arriola"

EditorialKirk SmithNovember 1, 2019Pulmonary Toxicity, Lorlatinib, Brigatinib